|Articles|January 19, 2021
Screening developability and pre-formulation by HT-DLS
Author(s)Wyatt Technology
Assessing a drug candidate early in discovery and development minimizes the risk of costly downstream failure. This white paper illustrates the application of automated DLS for aggregation and stability investigations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
CDC Revises Childhood Immunization Schedule, Shifting Demand Dynamics
2
China Approves First Monthly Biologic for COPD
3
Industry Outlook 2026: Biopharma Braces for Economic Upheaval While Eyeing AI-Driven Transformation (Part 1)
4
What Are the Benefits of Single-Use in CGT Manufacturing?
5